Clinical Trials Directory

Trials / Unknown

UnknownNCT02379000

TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy

Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Charite University, Berlin, Germany · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Proton beam therapy is a safe irradiation modality for choroidal melanoma. But often after irradiation the exudation increases resulting in an exudative retinal detachment requiring vitreoretinal surgery. It is known that intravitreally injected triamcinolone and TTT is capable to decrease the exudation. If there is any advantage in a combined treatment this study will investigate.

Detailed description

Proton beam therapy is an eye preserving irradiation modality for uveal melanoma. After proton beam therapy tumor related lipid exudation and exudative retinal detachment often increase. Therefore vitreoretinal surgery is sometimes required to reattach the retina to protect visual acuity. It is known that intravitreally injected triamcinolone and TTT is capable to decrease exudation. If there is any advantage in a combined treatment and if it is that effective to possibly avoid vitreoretinal surgery this study will investigate.

Conditions

Interventions

TypeNameDescription
DRUGTriamcinolone AcetonideUnder sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
PROCEDURETranspupillary thermotherapyWe delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.

Timeline

Start date
2015-01-01
Primary completion
2017-12-01
Completion
2018-07-01
First posted
2015-03-04
Last updated
2017-02-08

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02379000. Inclusion in this directory is not an endorsement.